The new rosiglitazone story: its place today in type 2 diabetes management.

Abstract

ADOPT suggests that rosiglitazone, ahead of traditional therapies, can meet patient needs with respect to long-term glycaemic control, yet the recent safety debate, stimulated by retrospective meta-analysis, has seriously affected physician confidence to use it. Other recent evidence, including from a number of long-term outcome studies, does not confirm or exclude a cardiovascular risk signal for rosiglitazone, and evaluation of this data has led EMEA to support continued use of rosiglitazone, albeit with a recommendation not to use in patients with a previous cardiovascular history. Where does this leave us? Rosiglitazone remains the only oral blood glucose lowering agent to have demonstrated nearly 5 years of blood glucose control. Patients earlier in their disease, free of known cardiovascular disease, are just the patients to benefit most from long term glucose target achievement.

• Authors: Phil Ambery, Bee Pandya
• Journal: Primary care diabetes (Prim Care Diabetes) Vol. 3 Issue 1 Pg. 57-9 (Feb 2009) ISSN: 1878-0210 [Electronic] England
• PMID: 19269912 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Thiazolidinediones
• Rosiglitazone

Topics

• Administration, Oral
• Blood Glucose (drug effects)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Evidence-Based Medicine
• Heart Diseases (chemically induced)
• Humans
• Hypoglycemic Agents (administration & dosage, adverse effects, therapeutic use)
• Patient Selection
• Practice Guidelines as Topic
• Risk Assessment
• Rosiglitazone
• Thiazolidinediones (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome